RxDoctor Payments Data

Aric Gregson, MD

Infectious Disease · Los Angeles, CANPI 1588683007

Payments from drug & device makers

$161,309in general payments, 2019–2025

Across 28 payments — averaging $5761.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$140K
  • Novartis$21K
  • Astellas Pharma US Inc$68

What the payments were for

  • Food & beverage$68100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron23$139,947
Novartis2$21,294
Astellas Pharma US Inc3$68

How this compares

$161,309 in reported general payments places this provider in the 90th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$258,327
Medicare patients
591
Services billed
2,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala12$54,467

Paid to pharmacies, not to this prescriber.

Other infectious disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →